|D007153||Immunologic Deficiency Syndromes NIH||0.41|
There is one clinical trial.
The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.
Description: Improvement of clinical symptoms including duration of fever, respiratory destress, pneumonia, cough, sneezing, diarrhea.Measure: Clinical outcome Time: 3 weeks
Description: Side effects measured by Chest ReadiographMeasure: CT Scan Time: 3 weeks
Description: Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negativeMeasure: RT-PCR results Time: 3 weeks
Description: Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negativeMeasure: RT-PCR results Time: 8 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports